Biotech Company Achoagen Taps Latham for $72 Million IPO
SAN FRANCISCO — Achoagen, a South San Francisco-based biopharmaceutical company, tapped a team from Latham & Watkins for counsel on its $72 million initial public offering. A team from Davis Polk advised the underwriters.
This article has been archived, and is no longer available on this website.
Not a LexisNexis® Subscriber?
For questions call 1-877-256-2472 or contact us at firstname.lastname@example.org